Use and Misuse of Opioid Replacement Therapies: A Queensland Study

REFERENCES

• Alho, H., Sinclair, D., Vuori, E., & Holopainen, A. (2007). Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug and Alcohol Dependence, 88, 75–78.
   PubMed Web of Science ®Google Scholar
• Auriacombe, M., Fatséas, M., Dubernet, J., Daulouède, J., & Tignol, J. (2004). French field experience with buprenorphine. The American Journal on Addictions / American Academy of Psychiatrists in Alcoholism and Addictions, 13(Suppl. 1), S17–S28.
   PubMed Web of Science ®Google Scholar
• Auriacombe, M., Franques, P., & Tignol, J. (2001). Deaths attributable to methadone vs buprenorphine in France. JAMA: The Journal of the American Medical Association, 285(1), 45.
   PubMed Web of Science ®Google Scholar
• Bell, J. R., Butler, B., Lawrance, A., Batey, R., & Salmelainen, P. (2009). Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug and Alcohol Dependence, 104(1–2), 73–77.
   PubMed Web of Science ®Google Scholar
• Boeuf, O., & Lapeyre-Mestre, M. (2007). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: Results of OSIAP survey. Drug Safety: An International Journal of Medical Toxicology and Drug Experience, 30(3), 265–276.
   PubMed Web of Science ®Google Scholar
• Chawarski, M. C., Schottenfeld, R. S., O'Connor, P. G., & Pakes, J. (1999). Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug and Alcohol Dependence, 55(1–2), 157–163.
   PubMed Web of Science ®Google Scholar
• Comer, S. D., & Collins, E. D. (2002). Self-administration of intravenous buprenorphine and the buprenorphine/naloxone combination by recently detoxified heroin abusers. The Journal of Pharmacology and Experimental Therapeutics, 303(2), 695–703.
   PubMed Web of Science ®Google Scholar
• Degenhardt, L., Larance, B. K., Bell, J. R., Winstock, A. R., Lintzeris, N., Ali, R. L., (2009). Injection of medications used in opioid substitution treatment in Australia after the introduction of a mixed partial agonist–antagonist formulation. The Medical Journal of Australia, 191(3), 161–165.
   PubMed Web of Science ®Google Scholar
• Fudala, P. J., Bridge, T. P., Herbert, S., Williford, W. O., Chiang, C. N., Jones, K., (2003). Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. The New England Journal of Medicine, 349(10), 949–958.
   PubMed Web of Science ®Google Scholar
• Fudala, P. J., Yu, E., Macfadden, W., Boardman, C., & Chiang, C. N. (1998). Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug and Alcohol Dependence, 50(1), 1–8.
   PubMed Web of Science ®Google Scholar
• Johansen, S. S, Jacobsen, C., Müller, I. B., Petersen, H. W., Simonsen, K. W., Kringsholm, B., (2006). [Fatal cases of poisoning in eastern Denmark during a five-year period (1998–2002)]. Ugeskrift for Laeger, 168(39), 3326–3331.
   PubMedGoogle Scholar
• Kakko, J., Grönbladh, L., Svanborg, K. D., von Wachenfeldt, J., Rück, C., Rawlings, B., (2007). A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: A randomized controlled trial. The American Journal of Psychiatry, 164(5), 797–803.
   PubMed Web of Science ®Google Scholar
• Kintz, P. (2001). Deaths involving buprenorphine: A compendium of French cases. Forensic Science International, 121(1–2), 65–69.
   PubMed Web of Science ®Google Scholar
• Kintz, P. (2002a). Buprenorphine-related deaths deaths. In: P. Kintz & P. Marquet (Eds.), Buprenorphine therapy of opiate addiction (pp. 109–118). Totowa, NJ: Humana Press.
   Google Scholar
• Kintz, P. (2002b). A new series of 13 buprenorphine-related deaths. Clinical Biochemistry, 35(7), 513–516.
   PubMed Web of Science ®Google Scholar
• Lewis, J. W. (1985). Buprenorphine. Drug and Alcohol Dependence, 14(3–4), 363–372.
   PubMed Web of Science ®Google Scholar
• Lintzeris, N., Mitchell, T. B., Bond, A. J., Nestor, L., & Strang, J. (2007). Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose conditions in opioid dependent patients. Drug and Alcohol Dependence, 91(2–3), 187–194.
   PubMed Web of Science ®Google Scholar
• Mendelson, J., & Jones, R. T. (2003). Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment? Drug and Alcohol Dependence, 70(2 Suppl.), S29–S37.
   PubMedGoogle Scholar
• Mendelson, J., Jones, R. T., Fernandez, I., Welm, S., Melby, A. K., & Baggott, M. J. (1996). Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clinical Pharmacology and Therapeutics, 60(1), 105–114.
   PubMed Web of Science ®Google Scholar
• Mendelson, J., Jones, R.T., Welm, S., Baggott, M., Fernandez, I., Melby, A.K., (1999). Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology, 141(1), 37–46.
   PubMed Web of Science ®Google Scholar
• Nielsen, S., Dietze, P., Lee, N., Dunlop, A., & Taylor, D. (2007). Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment. Addiction (Abingdon, England), 102(4), 616–622.
   PubMed Web of Science ®Google Scholar
• Queensland Needle and Syringe Program. (2009). Needle and syringe program policy. Brisbane: Queensland Needle and Syringe Program, Queensland Health.
   Google Scholar
• Tracqui, A., Tournoud, C., Flesch, F., Kopferschmitt, J., Kintz, P., Deveaux, M., (1998). [Acute poisoning during substitution therapy based on high-dosage buprenorphine. 29 clinical cases: 20 fatal cases]. Presse Médicale (Paris, France: 1983), 27(12), 557–561.
   PubMed Web of Science ®Google Scholar
• Treloar, C., & Cao, W. (2005). Barriers to use of needle and syringe programmes in a high drug use area of Sydney, New South Wales. International Journal of Drug Policy, 16(5), 308–315.
   Web of Science ®Google Scholar
• Walsh, S. L., Preston, K. L., Bigelow, G. E., & Stitzer, M. L. (1995). Acute administration of buprenorphine in humans: Partial agonist and blockade effects. The Journal of Pharmacology and Experimental Therapeutics, 274(1), 361–372.
   PubMed Web of Science ®Google Scholar
• Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994). Clinical pharmacology of buprenorphine: Ceiling effects at high doses. Clinical Pharmacology and Therapeutics, 55(5), 569–580.
   PubMed Web of Science ®Google Scholar